NanoViricides, Inc. (NYSE American: NNVC) announced that the Pillar Committee in Charge in the Democratic Republic of Congo has approved the company’s proposal to conduct a Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The approval marks a significant step forward for the company’s broad-spectrum antiviral candidate, which targets host-cell features required by viruses. According to the company, NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical testing.
The next steps include obtaining approvals from the DRC National Ethics Committee and regulatory agency ACOREP before initiating the study. NanoViricides noted that NV-387 Oral Gummies have already received authorization in the DRC for a Phase II mpox trial and are ready for shipment. Management believes the oral formulation could offer significant advantages in resource-limited outbreak settings, where intravenous treatments can be difficult to deploy and scale. The full press release is available at https://nnw.fm/1ewVT.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. The company’s platform technology and programs are based on the TheraCour nanomedicine technology, licensed from TheraCour Pharma, Inc. For more information, visit the company’s newsroom at https://nnw.fm/NNVC.
The approval to advance the Phase II Ebola trial underscores the potential of oral antiviral treatments in managing outbreaks, particularly in regions with limited healthcare infrastructure. If successful, NV-387 could provide a more accessible and scalable option compared to intravenous therapies, which require trained personnel and cold chain logistics. This development is especially relevant given the ongoing Bundibugyo ebolavirus outbreak in the DRC, where rapid deployment of treatments is critical.
NanoViricides’ business model focuses on licensing technology from TheraCour Pharma for specific virus applications. The company holds exclusive licenses for several human viral diseases, including HIV, Hepatitis B and C, Rabies, Herpes, Influenza, Dengue, Japanese Encephalitis, West Nile, Ebola/Marburg, and certain Coronaviruses. The company intends to obtain licenses for RSV, Poxviruses, and Enteroviruses pending successful research.
As with any drug development, there are risks. The company notes that the path to typical drug development is lengthy and requires substantial capital. There can be no assurance that NV-387 will show sufficient effectiveness and safety in human clinical trials. However, the DRC approval represents a crucial milestone in advancing a novel oral antiviral against Ebola, potentially transforming outbreak response strategies.
